Lopinavir (ABT-378) is an antiretroviral of the protease inhibitor class. It is marketed by Abbott as Kaletra (high-income countries) and Aluvia (low-income countries), both of which represent a co-formulation with a sub-therapeutic dose of ritonavir, as a component of combination therapy to treat HIV/AIDS. The Kaletra formulation has also been used successfully as monotherapy in some studies. Aidsmap | Kaletra monotherapy as effective as triple therapy for at least 18 months As of 2006, lopina… (More on Lopinavir)